PTPRC and gastric cancer: Neutralizing anti-IL-6 and/or IL-8 Abs and an arginase I inhibitor were added separately or altogether following 50% GC patient serum addition to the CD45+CD33lowCD11bdim myeloid and CD8+ T cell co-cultures.